Skip to main content Accessibility help

Risk Factors for Gastrointestinal Tract Colonization with Extended-Spectrum β-Lactamase (ESBL)–Producing Escherichia coli and Klebsiella Species in Hospitalized Patients

  • Jennifer H. Han (a1), Irving Nachamkin (a2), Theoklis E. Zaoutis (a3) (a4), Susan E. Coffin (a3) (a4), Darren R. Linkin (a1) (a3) (a5), Neil O. Fishman (a1), Mark G. Weiner (a6), Baofeng Hu (a2), Pam Tolomeo (a3) (a7) and Ebbing Lautenbach (a1) (a3) (a7)...


We describe the prevalence of and risk factors for colonization with extended-spectrum β-lactamase (ESBL)–producing Escherichia coli and Klebsiella species (ESBL-EK) in hospitalized patients. The prevalence of colonization with ESBL-EK was 2.6%. Colonization was associated with cirrhosis, longer duration of hospital stay prior to surveillance, and prior exposure to clindamycin or meropenem.


Corresponding author

Division of Infectious Diseases, Department of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, 3rd Floor, Silverstein Building, Suite E, Philadelphia, PA 19104 (


Hide All
1. Schwaber, MJ, Navon-Venezia, S, Kaye, KS, Ben-Ami, R, Schwartz, D, Carmeli, Y. Clinical and economic impact of bacteremia with extended-spectrum-β-lactamase–producing Enterobacteriaceae . Antimicrob Agents Chemother 2006;50:12571262.
2. Pena, C, Pujol, M, Ricart, A, et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum β-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect 1997;35:916.
3. Thouverez, M, Talon, D, Bertrand, X. Control of Enterobacteriaceae producing extended-spectrum beta-lactamase in intensive care units: rectal screening may not be needed in non-epidemic situations. Infect Control Hosp Epidemiol 2004;25:838841.
4. Friedmann, R, Raveh, D, Zartzer, E, et al. Prospective evaluation of colonization with extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing Enterobacteriaceae among patients during hospitalization. Infect Control Hosp Epidemiol 2009;30:534542.
5. Reddy, P, Malczynski, M, Obias, A, et al. Screening for extended-spectrum β-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis 2007;45:846852.
6. Harris, AD, McGregor, JC, Johnson, JA, et al. Risk factors for colonization with extended-spectrum β-lactamase–producing bacteria and intensive care unit admission. Emerg Infect Dis 2007;13:11441149.
7. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. CLSI documen M100-S20. Wayne, PA: CLSI, 2010.
8. McGettigan, SE, Hu, B, Andreacchio, K, Nachamkin, I, Edelstein, PH. Prevalence of CTX-M #x03B2;-lactamases in Philadelphia, Pennsylvania. J Clin Microbiol 2009;47:29702974.
9. Tumbarello, M, Sanguinetti, M, Montuori, E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007;51:19871994.
10. Song, KH, Jeon, JH, Park, WB, et al. Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study. BMC Infect Dis 2009;9:41.


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed